BioSpace News Archive

Accent Therapeutics presents advances in cancer targeting at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego, California.

Medicure Inc. (“Medicure” or the “Company”) (TSXV:MPH)(OTCPINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter and year ended December 31, 2023.

OKYO Pharma Limited (NASDAQ: OKYO) announces that it will be rescheduling a Key Opinion Leader (KOL) event entitled “KOL Event Presenting Comprehensive Detailed Results from the Phase 2 Trial of OK-101 in Dry Eye Disease” originally planned for April 9th, 2024 at 12:00 PM ET until May 2024.

Adcentrx Therapeutics (“Adcentrx”), a biotechnology company revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, announced today the appointment of Meng Jiang as Chief Financial Officer (CFO).

Opthea Limited announced the appointment of John Han, PharmD, to the role of Vice President, Medical Affairs, effective April 9, 2024.

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”) today announced additional results from the APOLLO phase 1 study of zerlasiran (SLN360) in subjects with baseline lipoprotein(a), or Lp(a), levels at or over 150 nmol/L were published in the Journal of the American Medical Association (JAMA).

Researchers with City of Hope®, one of the largest cancer research and treatment organizations in the United States, will present more than 70 abstracts and sessions on innovative clinical trial results, breakthrough diagnostic techniques and advances in treatment options as well as share their expertise on molecular profiling and the microbiome at the AACR Annual Meeting, which started April 5 and ends April 10 in San Diego.

Notable Labs, Ltd., a clinical-stage precision oncology company developing a new class of cancer therapies identified by its Predictive Precision Medicine Platform, presented data related to innovations in the use of cryopreserved samples in the PPMP assay at the American Association for Cancer Research being held in San Diego, CA.

Adela, Inc. presented initial results demonstrating the ability of its MRD assay to predict recurrence in head & neck cancer, at the American Association for Cancer Research (AACR) Annual Meeting from April 5-10, 2024.

AbCellera (Nasdaq: ABCL) today announced new data on its T-cell engager (TCE) programs at the American Association for Cancer ResearchⓇ (AACR) Annual Meeting 2024 at the San Diego Convention Center, with three posters being presented on April 8 and one on April 9.